OBJECTIVE: This study was designed to evaluate the potential usefulness of the @entity2692 -releasing intrauterine system (LNG IUS) in treating @entity1 with uterine @entity2909 . DESIGN: Prospective before-and-after study. SETTING: Family planning unit in an @entity4207 . @entity1 (S): Sixty-seven @entity1 with uterine @entity2909 who chose the LNG IUS as their method of contraception. INTERVENTION(S): Clinical and ultrasound examinations were performed prior to and 3, 6, and 12 months after the LNG IUS insertion. MAIN OUTCOME MEASURE(S): Menstrual @entity190 assessed with pictorial @entity190 assessment charts, ferritin and hemoglobin concentrations, and uterine and @entity2909 volume. RESULT(S): Use of the LNG IUS was associated with a marked @entity190 . After 12 months of use, the mean pictorial @entity190 assessment chart score declined from 97 to 16 (P<.001). Hemoglobin and ferritin levels increased significantly over 1 year of use. Eighteen of 19 @entity1 (95%) who were anemic at the beginning of the study were no longer anemic at 12 months, as judged by hemoglobin levels. No pregnancies occurred during the study. CONCLUSION(S): The LNG IUS was associated with a profound @entity190 . For @entity1 with @entity2909 of this size, the LNG IUS provides effective medical treatment of @entity548 .

Use of a XXXX -releasing intrauterine system to treat @entity548 related to uterine @entity2909 .

@entity1 :: ('9606', 'Species') :: ['women', 'PATIENT'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss', 'reduction in menstrual blood loss'] @entity2692 :: ('MESH:D016912', 'Chemical') :: ['levonorgestrel'] @entity4207 :: ('MESH:D007859', 'Disease') :: ['academic research institute'] @entity2909 :: ('MESH:D007889', 'Disease') :: ['leiomyomas', 'leiomyoma']
@entity2692 :: (MESH:D016912,Chemical) :: ['levonorgestrel']
